Athenex, a US-China oncology company, wrangled a $225 million manufacturing facility from New York State, which adds capacity to the two plants Chongqing is already building for the company; Genexine of Korea out-licensed China rights for a novel long-acting EPO drug to a subsidiary of Shanghai Fosun Pharma in a $44.5 million deal; Wanbang Biopharma, also a subsidiary of Shanghai Fosun Pharma, paid $39 million for China rights for two renal disease drugs from Rockwell Medical of the US; China’s State Council announced new rules to promote technology transfer from research institutes to small businesses, including allocating 50% of the profits to researchers; and Alibaba showed off its pilot mobile healthcare program, involving physician visits, prescriptions and drug purchases -- all online.
